Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats

5Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Ivacaftor is a modern drug used in the treatment of cystic fibrosis. It is highly lipophilic and exhibits a strong positive food effect. These characteristics can be potentially connected to a pronounced lymphatic transport after oral administration. Methods: A series of studies was conducted to describe the basic pharmacokinetic parameters of ivacaftor in jugular vein cannulated rats when dosed in two distinct formulations: an aqueous suspension and an oil solution. Additionally, an anesthetized mesenteric lymph duct cannulated rat model was studied to precisely assess the extent of lymphatic transport. Results: Mean ± SD ivacaftor oral bioavailability was 18.4 ± 3.2% and 16.2 ± 7.8%, respectively, when administered as an aqueous suspension and an oil solution. The relative contribution of the lymphatic transport to the overall bioavailability was 5.91 ± 1.61% and 4.35 ± 1.84%, respectively. Conclusion: Lymphatic transport plays only a minor role in the process of ivacaftor intestinal absorption, and other factors are, therefore, responsible for its pronounced positive food effect.

Cite

CITATION STYLE

APA

Pozniak, J., Ryšánek, P., Smrčka, D., Kozlík, P., Křížek, T., Šmardová, J., … Slanař, O. (2024). Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1331637

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free